الوصف

CYP2C*9 belongs to the cytochrome P**0 superfamily, which is expressed in the liver and involved in the metabolism of exogenous substances, including a variety of drugs. It is an important drug metabolism enzyme in the human body. CYP2C*9 gene polymorphism causes the change of CYP2C*9 enzyme activity. It affects drug metabolism, and further drug efficacy, or it aggravates drug side effects. The common polymorphisms of CYP2C*9 were weak metabolisms *2 (c.**1G>A, rs*******5), *3(c.**6G>A, rs******3) and super metabolisms **7(c.***6C>T, rs*******0). According to the difference of enzyme activity, CYP2C*9 can be divided into four phenotypes: ultra-fast metabolizer (UM), extended metabolizer (EM), intermediate metabolizer (IM), and slow metabolizer (PM). Among Asians, ****0% of CYP2C*9 carriers are slow metabolism (PM), and 4% of them are ultra-fast metabolism * *7 carriers. According to reports in the literature, CYP2C*9 is involved in the metabolism of ****5% of clinical medications such as clopidogrel, voriconazole, proton pump inhibitors, antidepressants, and antiepileptic drugs.
This kit, the CYP2C*9*2、*3、**7 polymorphism of CYP2C*9 gene is detected qualitatively by using the temperature difference between the probe and different alleles. Primers were designed to amplify the site, and then the melt curve of the specific probe labeled by fluorescence and the amplified product was used to determine the genotype of the sample at the site. Different genotypes have different melt peaks and different TM values, which realize the qualitative analysis of the detection results.